miR-33b-3p Acts as a Tumor Suppressor by Targeting DOCK4 in Prostate Cancer

Supplementary Figures

**Supplementary Figure 1** | Cell viability post bortezomib treatment in prostate cancer cells. (A) LNCaP, 22RV1, PC3 and DU145 cells were treated with bortezomib up to 160 nM for 72 h, and cell viability was analyzed by MTT assay.

**Supplementary Figure 2** | Overexpression of miR-33b-3p. RT-qPCR analysis of miR-33b-3p expression in LNCaP (A) and PC3 (B) cells transfected with miR-33b-3p
mimcs (miR-33b-3p) or negative control (mimic-NC) for 48 h. Data are presented as mean ± SD. ***$P < 0.001$ by two-tailed Student's $t$-test.

**Supplementary Figure 3** | The expression of miR-33b-3p in prostate cancer patients with different TNM stages. The expression of miR-33b-3p in prostate cancer patients with different T stages (A) and M stage (B) in TCGA. ns, no significance.

**Supplementary Figure 4** | The expression of DOCK4 and survival analysis in prostate cancer patients with different TNM stages. The expression of DOCK4 in prostate cancer patients with different T stages in TCGA (A) and N stage in UALCAN datasets (B). ns, no significance. (C) Kaplan-Meier curve of disease-free
survival of prostate cancer patients analyzed by using GEPIA. Blue curve represents patients with low expression of DOCK4, red curve represents patients with high expression of DOCK4.